

FOR YOUR INFORMATION ONLY - NOT FOR PROPOSAL SUBMISSION!

DKTK JOINT FUNDING 2026

PILLAR 1 THERAPEUTIC INNOVATIONS

! IMPORTANT INFORMATION

This information sheet must not be used for proposal submission, but lists the requirements and details that will be needed for a Pillar 1 project.

Short Proposals can only be submitted via the DKTK Application portal upon opening of the Call in mid-January until February 17, 2026 (13:00 CET). Access information will be provided.

1. PROJECT IDENTIFIER

Please provide a title for the project (up to 200 characters) and its publicly recognized acronym or abbreviation (up to 7 characters).

Project title Acronym

2. APPLICANTS

Overall Project Coordinator

The Overall Project Coordinator acts as primary contact person and is responsible for project coordination across participating sites and for annual project reporting. The Overall Project Coordinator must be a DKTK Faculty member, Investigator, or School of Oncology Fellow.

First name	Last name	Partner site	Main employer	E-Mail address
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Local Project Coordinator(s)

Each participating DKTK site must appoint at least **one Local Project Coordinator**. If multiple are listed for one site, one must be selected as the **primary** contact and person coordinating the local project activities. Non-DKTK members may be listed, if they qualify to obtain DKTK Investigator status.

First name	Last name	Partner site	Main employer	E-Mail address	Primary
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="checkbox"/>

Only in the case of additional Local Coordinators, please provide their first and last name, partner site, main employer, and email address, separated by ";". For example: Jane Doe, partner site AB, Universitätsklinikum XYZ, jane.doe@XYZ.de; John Doe, partner site CD...

External Research Partners

If applicable, list researchers who will contribute to the project, but are not located at a DKTK partner institution. Please note that budget can not be allocated to external research partners.

First name	Last name	Institution	E-Mail address
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

External Service Providers

Optional: Do you plan to include external service providers? More comprehensive information can be provided at the Full Proposal stage.

(Company) Name	Comment
<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>

3. RESEARCH SUMMARY

Background and significance

Please provide an overview of the research proposal's background and significance, ensuring that the following questions are addressed (max. 3500 characters incl. spaces): i) What unmet medical need(s) does this research address? ii) What are the envisioned future applications or clinical trials for this research? iii) What is the novelty and translational potential of the project? iv) What advantage does the envisioned intervention or application offer over existing therapies?

Proof of concept and previous work

Please describe the preliminary data and proof of concept obtained so far, including assessment of feasibility (max. 2000 characters, incl. spaces). Address how each entry **criterion** is met (max. 250 characters). Clearly indicate entry criteria that are not met or are not applicable.

! Mode of Action (MoA) / Target disease

! Validated target *(for systemic treatment or combined therapy)*

! On target activity *(for systemic treatment or combined therapy)*

! *In vitro* / *In vivo* efficacy in multiple models

! Predictive Biomarker hypothesis

Please note that further entry criteria are available on the next page

Proof of concept and previous work (continued)

1 Clinical pharmacology: achievable concentrations / PK in humans (for systemic treatment or combined therapy)

1 Diagnostic / toxicological data

1 Pharma interest in supporting trial in case preclinical package looks promising/is available (for systemic treatment or combined therapy)

1 Target cohort (specify patient cohort)

1 IP information, intellectual ownership

If your project has specific requirements (e.g. for technology developments), you may suggest additional criteria and provide comments on each (max. 250 characters per criteria).

Research Plan

Please describe your primary hypothesis and provide a brief description of the experimental approach including specific aims. The research plan should provide clear deliverables and timelines for a max. two-year research period. Describe for each investigator, which specific contribution is essential for the success of this project (max. 4000 characters incl. spaces).

4. DECLARATION AND DATA PROTECTION CONFIRMATION

The Overall Project Coordinator will be responsible that all listed investigators have read and agreed with the proposal, and with the data protection information. She/he will have to confirm this step before online submission. There is no signature process for the Short Proposal.

Proposals will only be accepted via the DKTK Application portal by February 17, 2026. Access information will be shared in mid-January 2026.